<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Emetic risk of single intravenous antineoplastic agents in adults</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Emetic risk of single intravenous antineoplastic agents in adults</h1>
<div class="graphic"><div class="figure"><div class="ttl">Emetic risk of single intravenous antineoplastic agents in adults</div><div class="cntnt"><table cellspacing="0" class="container"><colgroup span="2" width="50%"></colgroup> <tbody> <tr> <td class="container"> <table cellspacing="0"> <colgroup width="30%"></colgroup><colgroup width="70%"></colgroup> <tbody> <tr> <td class="subtitle1">Risk level</td> <td class="subtitle1">Agent</td> </tr> <tr> <td class="divider_bottom" rowspan="7">High (&gt;90%)</td> <td>Anthracycline/cyclophosphamide combination</td> </tr> <tr> <td>Carmustine</td> </tr> <tr> <td>Cisplatin</td> </tr> <tr> <td>Cyclophosphamide ≥1500 mg/m<sup>2</sup></td> </tr> <tr> <td>Dacarbazine</td> </tr> <tr> <td>Mechlorethamine</td> </tr> <tr class="divider_bottom"> <td>Streptozocin</td> </tr> <tr> <td class="divider_bottom" rowspan="23">Moderate (30 to 90%)</td> <td>Alemtuzumab</td> </tr> <tr> <td>Arsenic trioxide</td> </tr> <tr> <td>Azacitidine</td> </tr> <tr> <td>Bendamustine</td> </tr> <tr> <td>Busulfan*</td> </tr> <tr> <td>Carboplatin</td> </tr> <tr> <td>Clofarabine</td> </tr> <tr> <td>Cyclophosphamide &lt;1500 mg/m<sup>2</sup></td> </tr> <tr> <td>Cytarabine &gt;1000 mg/m<sup>2</sup></td> </tr> <tr> <td>Daunorubicin</td> </tr> <tr> <td>Daunorubicin and cytarabine liposome</td> </tr> <tr> <td>Doxorubicin</td> </tr> <tr> <td>Epirubicin</td> </tr> <tr> <td>Fam-trastuzumab deruxtecan-nxki</td> </tr> <tr> <td>Idarubicin</td> </tr> <tr> <td>Ifosfamide</td> </tr> <tr> <td>Irinotecan</td> </tr> <tr> <td>Irinotecan liposomal injection</td> </tr> <tr> <td>Oxaliplatin</td> </tr> <tr> <td>Romidepsin</td> </tr> <tr> <td>Temozolomide<sup>¶</sup></td> </tr> <tr> <td>Thiotepa<sup>Δ</sup></td> </tr> <tr class="divider_bottom"> <td>Trabectedin</td> </tr> <tr> <td rowspan="19">Low (10 to 30%)</td> <td>Aflibercept</td> </tr> <tr> <td>Axicabtagene ciloleucel</td> </tr> <tr> <td>Belinostat</td> </tr> <tr> <td>Blinatumomab</td> </tr> <tr> <td>Bortezomib</td> </tr> <tr> <td>Brentuximab</td> </tr> <tr> <td>Cabazitaxel</td> </tr> <tr> <td>Carfilzomib</td> </tr> <tr> <td>Catumaxumab</td> </tr> <tr> <td>Cetuximab</td> </tr> <tr> <td>Copanlisib</td> </tr> <tr> <td>Cytarabine ≤1000 mg/m<sup>2</sup></td> </tr> <tr> <td>Decitabine</td> </tr> <tr> <td>Docetaxel</td> </tr> <tr> <td>Elotuzumab</td> </tr> <tr> <td>Enfortumab vedotin-ejfv</td> </tr> <tr> <td>Eribulin</td> </tr> <tr> <td>Etoposide</td> </tr> <tr> <td>Fluorouracil</td> </tr> </tbody> </table> </td> <td class="container"> <table cellspacing="0"> <colgroup width="30%"></colgroup><colgroup width="70%"></colgroup> <tbody> <tr> <td class="subtitle1">Risk level</td> <td class="subtitle1">Agent</td> </tr> <tr> <td class="divider_bottom" rowspan="22">Low (10 to 30%)<br/> (continued)</td> <td>Gemcitabine</td> </tr> <tr> <td>Gemtuzumab ozogamicin</td> </tr> <tr> <td>Inotuzumab ozogamicin</td> </tr> <tr> <td>Ixabepilone</td> </tr> <tr> <td>Methotrexate</td> </tr> <tr> <td>Mitomycin</td> </tr> <tr> <td>Mitoxantrone</td> </tr> <tr> <td>Moxetumomab pasudotox</td> </tr> <tr> <td>Nab-paclitaxel</td> </tr> <tr> <td>Necitumumab</td> </tr> <tr> <td>Nelarabine</td> </tr> <tr> <td>Paclitaxel</td> </tr> <tr> <td>Panitumumab</td> </tr> <tr> <td>Pegylated liposomal doxorubicin</td> </tr> <tr> <td>Pemetrexed</td> </tr> <tr> <td>Pertuzumab</td> </tr> <tr> <td>Tagraxofusp-erzs</td> </tr> <tr> <td>Temsirolimus</td> </tr> <tr> <td>Tisagenlecleucel</td> </tr> <tr> <td>Topotecan</td> </tr> <tr> <td>Trastuzumab-emtansine</td> </tr> <tr class="divider_bottom"> <td>Vinflunine</td> </tr> <tr> <td rowspan="26">Minimal (&lt;10%)</td> <td>Atezolizumab</td> </tr> <tr> <td>Avelumab</td> </tr> <tr> <td>Bevacizumab</td> </tr> <tr> <td>Bleomycin</td> </tr> <tr> <td> </td> </tr> <tr> <td>Cemiplimab</td> </tr> <tr> <td>2-Chlorodeoxyadenosine</td> </tr> <tr> <td>Cladribine</td> </tr> <tr> <td>Daratumumab</td> </tr> <tr> <td>Durvalumab</td> </tr> <tr> <td>Emapalumab</td> </tr> <tr> <td>Fludarabine</td> </tr> <tr> <td>Ipilimumab</td> </tr> <tr> <td>Nivolumab</td> </tr> <tr> <td>Obinutuzumab</td> </tr> <tr> <td>Ofatumumab</td> </tr> <tr> <td>Pembrolizumab</td> </tr> <tr> <td>Pixantrone</td> </tr> <tr> <td>Polatuzumab vedotin</td> </tr> <tr> <td>Pralatrexate</td> </tr> <tr> <td>Ramucirumab</td> </tr> <tr> <td>Rituximab</td> </tr> <tr> <td>Trastuzumab</td> </tr> <tr> <td>Vinblastine</td> </tr> <tr> <td>Vincristine</td> </tr> <tr> <td>Vinorelbine</td> </tr> </tbody> </table> </td> </tr> </tbody></table></div><div class="graphic_footnotes">* Reclassified based on errata.<sup>[1]</sup><br/>¶ No direct evidence found for intravenous temozolomide; because all sources indicate a similar safety profile to the oral formulation, the classification was based on oral temozolomide.<br/>Δ Classification refers to individual evidence from pediatric trials.</div><div class="graphic_reference">Reference:<br/><ol>
<li>Hesketh PJ, Kris MG, Basch E, et al. Antiemetics: ASCO guideline update: Errata. J Clin Oncol 2020; 38:3825</li>
</ol>

Reproduced with permission from: Hesketh PJ, Kris MG, Basch E, et al. Antiemetics: ASCO guideline update. J Clin Oncol 2020; 38:JCO2001296. Copyright © 2020 American Society of Clinical Oncology. All rights reserved.</div><div id="graphicVersion">Graphic 58756 Version 41.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
